5-[(1S)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)azaniumyl]-1-hydroxyethyl]-2-oxo-1H-quinolin-8-olate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-[(1S)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)azaniumyl]-1-hydroxyethyl]-2-oxo-1H-quinolin-8-olate
• 化学式: C24H28N2O3
• 分子量: 392.5
• InChiKey: QZZUEBNBZAPZLX-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  89
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'INDANAMINE ET DE NOUVEAUX INTERMÉDIAIRES DE SYNTHÈSE
  申请人：LABORATORIO CHIMICO INT SPA

  公开号：WO2016116857A1

  公开（公告）日：2016-07-28

  Subject-matter of the invention is a process for the preparation of a key intermediate in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates. Formula (I):

  发明的主题是一种制备吲哚卡特罗合成中间体的方法。发明的主题还包括新的合成中间体。公式(I)：
• A Process for Preparing Indacaterol and Salts Thereof
  申请人：REDDY G. Pratap

  公开号：US20180215714A1

  公开（公告）日：2018-08-02

  The present invention relates to a process for preparing indacaterol or salts thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 and compound of Formula 3 in the presence of a solvent to Form compound of Formula 4, which on removal of the protecting groups forms compound of Formula 1.

  本发明涉及一种制备吲达特罗或其盐的方法。该方法包括在溶剂存在下通过使化合物式2和化合物式3反应形成化合物式1的步骤，从而形成化合物式4，去除保护基后形成化合物式1。
• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140329814A2

  公开（公告）日：2014-11-06

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及制药组合物，包括上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物，该化合物为公式A、公式B、公式C或公式D。本发明还涉及该制药组合物的制药配方，以及使用该组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Process for preparing indacaterol and salts thereof
  申请人：Reddy G. Pratap

  公开号：US10227305B2

  公开（公告）日：2019-03-12

  The present invention relates to a process for preparing indacaterol or salts thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 and compound of Formula 3 in the presence of a solvent to Form compound of Formula 4, which on removal of the protecting groups forms compound of Formula 1.

  本发明涉及一种制备茚达特罗或其盐类的工艺。该工艺包括在溶剂存在下，通过式 2 化合物和式 3 化合物反应形成式 1 化合物，形成式 4 化合物，除去保护基团后形成式 1 化合物。
• BETA2-ADRENOCEPTOR AGONISTS
  申请人：NOVARTIS AG

  公开号：EP1183240B1

  公开（公告）日：2009-08-19